David Chang, Allogene CEO (Jeff Rumans)

Servi­er cuts off col­lab­o­ra­tion agree­ment with Al­lo­gene on CD19 prod­ucts, send­ing shares sput­ter­ing

Al­lo­gene Ther­a­peu­tics said in an SEC fil­ing to­day that French part­ner Servi­er has cut off its in­volve­ment in a part­ner­ship de­vel­op­ing ther­a­pies di­rect­ed against CD19, in­clud­ing the most ad­vanced can­di­dates in Al­lo­gene’s pipeline.

Shares of Al­lo­gene $AL­LO, an out­fit run by Kite vets Arie Bellde­grun and re­search chief David Chang, fell by al­most 10% on Wednes­day, even as the San Fran­cis­co-based com­pa­ny said that Servi­er’s dis­con­tin­u­a­tion “does not oth­er­wise af­fect our cur­rent ex­clu­sive li­cense for the de­vel­op­ment and com­mer­cial­iza­tion of CD19 Prod­ucts in the Unit­ed States.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.